Results 261 to 270 of about 18,416,887 (403)

Cancer stem cells

Annals of Oncology, 2008
openaire   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle. [PDF]

Cancers (Basel)
Ganesan IP, Kiyokawa H.
europepmc   +1 more source

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer [PDF]

Ying Cheng, Chunjiao Wu, Lin Wu, Jun Zhao, Yanqiu Zhao, Lulu Chen, Ying Xin, Liang Zhang, Pinhua Pan, Xingya Li, Juan Li, Xiaorong Dong, Ke Tang, Emei Gao, Fei Yu   +14 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

DACIT device for axon cancer cell interaction testing in 2D and 3D. [PDF]

iScience
Velazquez-Quesada I, Alizadeh V, Allison K, Belova E, Kallogjerovic S, Hesketh N, Zhang X, Thomas G, Tüzel E, Gligorijevic B.   +9 more
europepmc   +1 more source

Comparative Analysis of Aptamer-Conjugated Chemical and Green Synthesized Gold Nanoparticles for Targeted Therapy in MCF-7 Cancer Cells [PDF]

Mahmoud Helal, Miftah Faried, S. Ben Salah, Mazen Ashraf, Nada Nasser, Yasser Shawky, Sara Hamdy, Azza El Amir, Wajeet Nabil, Dalia M. El-Husseini   +9 more
openalex   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Protocol for fabrication and utilization of the device for axon-cancer cell interaction testing. [PDF]

STAR Protoc
Velazquez-Quesada I, Allison K, Alizadeh V, Tüzel E, Gligorijevic B.   +4 more
europepmc   +1 more source

Lung Immune Prognostic Index-Based Predictive Score in Advanced Non-Small Cell Lung Cancer with a Programmed Death Ligand-1 Tumor Proportion Score ≥ 50% [PDF]

Ari Raphael, Ayelet Kamm Feldman, Irina Lazarev, Waleed Kian, Nir Peled, Keren Hod, Walid Shalata, Elizabeth Dudnik   +7 more
openalex   +1 more source